Summary of COVID-19 defibrotide studies

1. Jara Rubio et al., Phase IIB, Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Intravenous Defibrotide for the Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome in COVID-19

150 patient defibrotide late treatment RCT: 23% higher mortality (p=0.56), 200% higher progression (p=0.14), no change in ICU admission (p=1), and 18% longer hospitalization (p=0.41).
RCT 150 hospitalized COVID-19 patients with respiratory failure showing no significant benefit with continuous IV defibrotide versus placebo.
May 2026, European J. Haematology, https://onlinelibrary.wiley.com/doi/10.1111/ejh.70214, https://c19p.org/jararubio